Cargando…
Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
BACKGROUND: Many patients with asthma have a T-helper type 2 (Th2) driven inflammation of the lung, whereas toll-like receptor 7 (TLR7) agonists, by inducing type I interferons, inhibit Th2 responses. In man, oral or parenteral TLR7 agonists can induce influenza-like symptoms through systemic induct...
Autores principales: | Delaney, Stephen, Biffen, Mark, Maltby, Justine, Bell, John, Asimus, Sara, Aggarwal, Ajay, Kraan, Maarten, Keeling, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769423/ https://www.ncbi.nlm.nih.gov/pubmed/26933507 http://dx.doi.org/10.1136/bmjresp-2015-000113 |
Ejemplares similares
-
Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013) -
Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis
por: Woodcock, Ashley, et al.
Publicado: (2022) -
Effectiveness, usability and acceptability of a smart inhaler programme in patients with asthma: protocol of the multicentre, pragmatic, open-label, cluster randomised controlled ACCEPTANCE trial
por: van de Hei, Susanne J, et al.
Publicado: (2022) -
What are the pros and cons of electronically monitoring inhaler use in asthma? A multistakeholder perspective
por: Howard, Sam, et al.
Publicado: (2016) -
Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review
por: Patel, Roshni, et al.
Publicado: (2020)